M. Gubin
Immunology · 2014–2019
A researcher in the Science corpus: 4 papers; trusts 4 researchers and is trusted by 2 researchers here, as inferred from the citation graph.
Subfields
- Immunology — 91 citations into it; #1,511 of 2,160 by trust here, #755 by citations
- Oncology — 76 citations into it; #1,208 of 1,698 by trust here, #503 by citations
Whom M. Gubin trusts overall
Their strongest outbound trust, strongest first, inferred from their citations.
Who trusts M. Gubin overall
Papers from M. Gubin's perspective
Ordered by how strongly the researchers M. Gubin trusts endorse each paper. Same corpus, a different order for every researcher.
- Safety, Activity, and Immune Correlates of Anti–PD-1 Antibody in Cancer (New England Journal of Medicine)
- Natural innate and adaptive immunity to cancer. (Annual Review of Immunology)
- Cancer-related inflammation (Nature)
- Cancer Exome Analysis Reveals a T Cell Dependent Mechanism of Cancer Immunoediting (Nature)
- CTLA-4 and PD-1 Receptors Inhibit T-Cell Activation by Distinct Mechanisms (Molecular and Cellular Biology)
- An immune-active tumor microenvironment favors clinical response to ipilimumab (Cancer Immunology and Immunotherapy)
- PD-1 and its ligands in tolerance and immunity. (Annual Review of Immunology)
- Clinical impact of different classes of infiltrating T cytotoxic and helper cells (Th1, th2, treg, th17) in patients with colorectal cancer. (Cancer Research)
- Exhaustion of tumor-specific CD8⁺ T cells in metastases from melanoma patients. (Journal of Clinical Investigation)
- Cancer immunoediting: from immunosurveillance to tumor escape (Nature Immunology)
Their papers
- Metabolic competition in the tumor microenvironment is a driver of cancer progression (2015) — 2,891 citations
- MHC-II neoantigens shape tumor immunity and response to immunotherapy (2019) — 733 citations
- New insights into cancer immunoediting and its three component phases — elimination, equilibrium and escape (2014) — 1,411 citations
- Checkpoint Blockade Cancer Immunotherapy Targets Tumour-Specific Mutant Antigens (2014) — 1,894 citations